Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases

Karla Ramos-Torres, Yu-Peng Zhou, Bo Yeun Yang, Nicolas Guehl, Sanjay Telu, Marc Normandin, Victor Pike and Pedro Brugarolas
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 619;
Karla Ramos-Torres
1Harvard Medical School Boston MA United States
2Gordon Center for Medical Research Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Peng Zhou
1Harvard Medical School Boston MA United States
2Gordon Center for Medical Research Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Yeun Yang
3National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Guehl
1Harvard Medical School Boston MA United States
2Gordon Center for Medical Research Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Telu
3National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Normandin
2Gordon Center for Medical Research Massachusetts General Hospital Boston MA United States
1Harvard Medical School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Pike
3National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Brugarolas
1Harvard Medical School Boston MA United States
2Gordon Center for Medical Research Massachusetts General Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

619

Objectives: Trifluoromethyl groups are of great interest in radiopharmaceuticals as they can enhance chemical and metabolic stability and allow for the manipulation of physicochemical properties such as pKa, lipophilicity and bioavailability1 while providing a handle that is amenable to labeling with carbon-112 or fluorine-183-7. Although most available methods are focused on 18F-labeling with [18F]fluoroformor its copper(I) derivative, the main limitation for PET radiotracer development lies in the low to moderate molar activities achievable by these methods. To address this problem, the synthesis of [11C]fluoroform from cyclotron-produced [11C]methane was recently developed, allowing for the retention of high molar activity and the labeling of small molecules with [11C]trifluoromethyl groups with molar activities exceeding 5.4 Ci/μmol2. Aminopyridines are of interest for the development of PET radiotracers. For example, radiolabeled derivatives of 4-aminopyridine (4AP), an FDA-approved drug for multiple sclerosis that binds to voltage-gated K+ channels present in demyelinated axons, have been proposed for PET imaging of demyelinating diseases. Here, we describe methods for producing [11C]trifluoromethyl derivatives of 4AP and present the first imaging results with [11C]3-trifluoromethyl-4-aminopyridine ([11C]3-CF3‑4AP) in a Rhesus macaque.

Methods: The [11C]fluoroform production method2 was adapted to generate [11C]methane from cyclotron-produced [11C]carbon dioxide using a GE Tracerlab FX MeI synthesizer. Subsequently, [11C]methane was converted into [11C]fluoroform by passing it through a heated reactor containing CoF3. This was then converted into the trifluoromethylating agent [11C]CuCF3 for the systematic investigation of its use to produce [11C]CF3-4AP derivatives from pyridines donning a halide group (iodo or bromo) at 2- or 3-position and an ester, amide or amine group at the 4-position. Finally, [11C]3-CF3-4AP was produced for preliminary imaging in a healthy Rhesus macaque. Dynamic PET data was acquired for 120 min after a slow bolus injection of 1.93 mCi of [11C]3-CF3‑4AP.

Results: Production of [11C]CHF3 compared well to previous reports. While the overall radiochemical yield from [11C]carbon dioxide, 52 ± 8% (n=15), was comparable to that from [11C]methane, changes to the gas flow to increase pressure and contact time between [11C]methane and CoF3 further improved the radiochemical purity of the [11C]fluoroform from about 80% to 94 ± 4% (n=15). Trifluoromethylation of bromo- and iodopyridine substrates containing electron-withdrawing (CO2Me) and electron-donating groups (NHBoc and NH2) with [11C]fluoroform resulted in a wide range of yields (5-97%), with iodo-precursors giving higher yields than their bromo counterparts. Dynamic PET imaging of [11C]3-CF3-4AP showed a fast high uptake of radioactivity in brain followed by a fast washout, similar to that reported for [18F]3-F-4AP8.

Conclusions: This work illustrates the versatility of labeling pyridines with [11C]fluoroform and provides initial evidence for the potential use of [11C]3-CF3‑4AP as a PET radioligand for demyelination. References: 1Purser S, Moore PR, Swallow S, et al. Chem Soc Rev 37, 320-330. 2Haskali MB, Pike VW. Chem Eur J 23, 8156-8160. 3Huiban M, Tredwell M, Mizuta S, et al. Nat Chem 5, 941-944. 4van der Born D, Sewing C, Herscheid JK, et al. Angew Chem Int Ed Engl 53, 11046-11050. 5Ruhl T, Rafique W, Lien VT, et al. Chem Commun (Camb) 50, 6056-6059. 6Ivashkin P, Lemmonier G, Cousin J, et al. Chemistry 20, 9514-9518. 7Carroll L, Evans HL, Spivey AC, et al. Chem Commun (Camb) 51, 8439-8441. 8Brugarolas P, Sánchez-Rodríguez JE, Tsai HM, et al. Sci Rep 8, 607.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases
Karla Ramos-Torres, Yu-Peng Zhou, Bo Yeun Yang, Nicolas Guehl, Sanjay Telu, Marc Normandin, Victor Pike, Pedro Brugarolas
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 619;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Syntheses of [11C]2- and [11C]3-trifluoromethyl-4-aminopyridine: potential PET radioligands for imaging demyelinating diseases
Karla Ramos-Torres, Yu-Peng Zhou, Bo Yeun Yang, Nicolas Guehl, Sanjay Telu, Marc Normandin, Victor Pike, Pedro Brugarolas
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 619;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • In vitro response of 177Lu-PSMA-617 with two different specific activities
  • ‘In-loop’ [11C]CO2fixation: Application to the synthesis of a 11C-labeled cholesterol 24-hydroxylase inhibitor
  • A Unique 18F-labeled G-protein-coupled receptor 44 (GPR44) radiotracer: design, radio-synthesis and evaluation in the rodents
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

New Radiotracers

  • In vitro response of 177Lu-PSMA-617 with two different specific activities
  • SPECT and PET imaging of CD11b-positive immune cells in an orthotopic mouse model of glioma with Zr-89 and Lu-177 labeled Lumi804-anti-CD11b antibody
Show more New Radiotracers

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire